Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer

First line treatment of patients with castrate resistant prostate cancer (CRPC) primarily involves administration of docetaxel chemotherapy. Unfortunately, resistance to docetaxel therapy is an ultimate occurrence. Alterations in androgen receptor (AR) expression and signaling are associated mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, ShengYu, Lasorsa, Elena, Adelaiye, Remi, Ramakrishnan, Swathi, Ellis, Leigh, Pili, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114978/
https://www.ncbi.nlm.nih.gov/pubmed/25072314
http://dx.doi.org/10.1371/journal.pone.0103680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114978/
https://www.ncbi.nlm.nih.gov/pubmed/25072314
http://dx.doi.org/10.1371/journal.pone.0103680

Ejemplares similares